Semax vs. Selank: A Research Comparison

Semax and Selank are routinely mentioned in the same breath, supplied in the same blends, and treated in a great deal of online writing as near-interchangeable. Chemically they are not. They share one design feature — a C-terminal Pro-Gly-Pro extension — and they came out of the same institutional research programme in Russia. Beyond that, they derive from different parent molecules, carry different sequences, behave differently in a chromatogram, and have separate research literatures. This article sets out what actually distinguishes them.

What Semax is: Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its first four residues correspond to positions 4 through 7 of adrenocorticotropic hormone (ACTH); the terminal Pro-Gly-Pro replaces the natural continuation of the hormone sequence. Its molecular formula is C37H51N9O10S, its average molecular weight is approximately 813.9 g/mol, and it is registered under CAS 80714-61-0 (PubChem CID 9811102).

What Selank is: Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Its first four residues are tuftsin, a naturally occurring tetrapeptide fragment derived from immunoglobulin G, again extended with Pro-Gly-Pro. Its molecular formula is C33H57N11O9, its average molecular weight is approximately 751.9 g/mol, and it is registered under CAS 129954-34-3 (PubChem CID 11765600).

Where the structures overlap: the shared element is the C-terminal Pro-Gly-Pro tripeptide. In both molecules it is a synthetic addition to a short natural fragment, and in both cases the published rationale is the same — proline-flanked termini are poorer substrates for the aminopeptidases and carboxypeptidases that rapidly clear short peptides, so the modified molecule persists longer than the unmodified fragment in experimental systems. This is a shared design strategy, not a shared pharmacology.

Where they diverge: the parent fragments have nothing in common. ACTH is a pituitary hormone; tuftsin is an immunoglobulin-derived tetrapeptide. The residues themselves differ correspondingly. Semax contains methionine and histidine and is comparatively neutral in character; Selank contains both lysine and arginine and is strongly basic. Neither molecule retains the functional identity of its parent: Semax is not ACTH and does not carry its corticotropic character, and Selank is not tuftsin.

Different research histories: both compounds originate from the Institute of Molecular Genetics of the Russian Academy of Sciences, within the neuropeptide research programme associated with I. P. Ashmarin, with Selank developed jointly with the Institute of Pharmacology of the Russian Academy of Medical Sciences. Semax is the older of the two, dating to the 1980s, and has the larger literature. Published research on Semax includes structure–activity work, animal models of cerebral ischaemia, a reported increase in brain-derived neurotrophic factor in rat basal forebrain after intranasal administration, and physicochemical characterisation of its copper(II) binding. Published research on Selank includes behavioural work in animal models, a small Russian comparative clinical study in anxiety-spectrum conditions with 62 participants, and more recent in-vitro work on gene expression in cultured neuronal cell lines.

Limitations of the evidence: these two literatures share a structural weakness that any researcher reading them should hold in view. The overwhelming majority of clinical and mechanistic work on both peptides originates from Russian institutions, is frequently published in Russian-language journals, and is often authored by groups connected to the original development programmes. Reported clinical studies are small, and by contemporary standards frequently not blinded or placebo-controlled. Independent replication outside Russia is limited. Recent in-vitro work published in English-language journals adds mechanistic detail but does not close the clinical evidence gap. Neither compound is an approved medicine outside that context, and nothing in this literature supports a statement about human use.

Analytical considerations: distinguishing the two in the laboratory is straightforward, and the reasons are worth understanding. Their average masses differ by roughly 62 g/mol, which is trivially resolvable by mass measurement. Their charge characteristics differ substantially — Selank's lysine and arginine residues make it markedly more basic than Semax — which gives them different retention behaviour on reversed-phase columns and allows both to be quantified individually within a combined preparation.

Each sequence also has its own degradation signature. Semax contains methionine, which oxidises to a species carrying a +16 mass shift and resolving as a separate chromatographic peak; watching for that peak is the practical stability check for Semax material. Selank has no methionine and no cysteine, so it is not subject to the same oxidation route, but its basic residues make it more sensitive to method conditions during chromatographic development.

Why documentation matters here: for two peptides of similar length, similar design and frequent co-supply, the analytical report is the only thing that establishes which molecule was present in the sample tested and how much of it there was. Identity can be established in more than one way — mass spectrometry compares a measured mass against a theoretical one, while current Vial Drop Labs reports establish it chromatographically, by retention-time and UV/DAD comparison against a reference standard. Purity is reported separately as the target peak's share of total integrated peak area, and content per vial separately again against label claim. In a combined preparation, all of it must be reported per component — a single number for a two-analyte blend describes nothing.

Vial Drop Labs publishes independent analytical reports for tested research materials, and available reports are published to the Research Documentation portal against the sample identified on each report. Each analytical report applies only to the sample submitted for analysis and should not be interpreted as testing of every vial or production unit. Nothing on this page is a statement about the results of any particular batch; the report itself is the only authoritative record of what was measured, by which method, and on which date.